Relationship between plasma pentraxin 3 level and risk of chronic kidney disease in the Korean elderly: the Dong-gu study
- 114 Downloads
Purpose This study investigated the cross-sectional association between chronic kidney disease (CKD) and plasma pentraxin 3 (PTX3) levels in a Korean population, in a community-based cohort study.
A total of 1816 (891 men, 925 women) subjects were randomly selected from the cohort of participants for the final analyses. Plasma PTX3 concentration was determined using enzyme-linked immunosorbent assays. The participants were divided into four quartiles according to the PTX3 levels. Multivariate logistic regression was performed to evaluate the association between plasma PTX3 level and CKD. Covariates inserted into the multivariate model included smoking status, systolic blood pressure, body mass index, waist circumference, high-density lipoprotein, low-density lipoprotein uric acid, white blood cell count, and carotid intima-media thickness.
Compared to the lowest PTX3 group (Q1), a significantly higher risk of CKD was found in the highest group (Q4), with an odds ratio of 1.58 and 95% confidence interval of 1.18–2.11 (P for trend <0.001).
This study showed that higher plasma PTX3 levels are significantly associated with CKD risk. The biological mechanism remains unclear; therefore, further molecular investigation of association between CKD and PTX3 is needed.
KeywordsPentraxin 3 Chronic kidney disease Community-based study
Compliance with ethical standards
Conflict of interest
All authors declare that he/she has no conflict of interests regarding the publication of this paper.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by Institutional Review Board of Chonnam National University Hospital.
- 1.National Kidney F (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266Google Scholar
- 2.Mortality GBD, Causes of Death C (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet 388(10053):1459–1544. doi: 10.1016/S0140-6736(16)31012-1 CrossRefGoogle Scholar
- 5.Kim S, Lim CS, Han DC, Kim GS, Chin HJ, Kim SJ, Cho WY, Kim YH, Kim YS (2009) The prevalence of chronic kidney disease (CKD) and the associated factors to CKD in urban Korea: a population-based cross-sectional epidemiologic study. J Korean Med Sci 24(Suppl):S11–S21. doi: 10.3346/jkms.2009.24.S1.S11 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Cas LD, Ghezzi P, Sipe JD, Re G, Olivetti G, Mantovani A, Latini R (2000) PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102(6):636–641CrossRefPubMedGoogle Scholar
- 8.Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimburger O, Barany P, Axelsson J, Alvestrand A, Stenvinkel P, Lindholm B, Suliman ME (2007) Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2(5):889–897. doi: 10.2215/CJN.00870207 CrossRefPubMedGoogle Scholar
- 9.Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA (2012) Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the heart and soul study. Am Heart J 163(2):274–279. doi: 10.1016/j.ahj.2011.11.007 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, Yenicesu M, Tong M, Heimburger O, Barany P, Alvestrand A, Lindholm B, Stenvinkel P (2008) Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 3(4):976–985. doi: 10.2215/CJN.03960907 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P (2009) Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 4(3):535–541. doi: 10.2215/CJN.04330808 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Simeoni M, Cianfrone P, Comi N, Gentile I, Fabiano FF, Piraina V, Talarico R, Lucisano G, Rivoli L, Andreucci M, Fuiano L, Foti D, Gulletta E, Fuiano G (2015) Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response? G Ital Nefrol 32(1):1–10Google Scholar
- 17.Cianfrone P, Simeoni M, Comi N, Piraina V, Talarico R, Cerantonio A, Gentile I, Fabiano FF, Lucisano G, Foti D, Gulletta E, Fuiano G (2017) How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT-a prospective cohort study. J Nephrol 30(1):95–102. doi: 10.1007/s40620-015-0256-3 CrossRefPubMedGoogle Scholar
- 19.Choi SW, Kim HY, Ahn HR, Lee YH, Kweon SS, Choi JS, Rhee JA, Nam HS, Jeong SK, Park KS, Ryu SY, Song HR, Shin MH (2013) Association of bone mineral density with albuminuria and estimated glomerular filtration rate: the Dong-gu study. Kidney Blood Press Res 37(2–3):132–141. doi: 10.1159/000350067 CrossRefPubMedGoogle Scholar
- 20.Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G, National Kidney F (2003) National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139(2):137–147CrossRefPubMedGoogle Scholar
- 21.Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, Ebrahim S, Fatar M, Hernandez RH, Kownator S, Prati P, Rundek T, Taylor A, Bornstein N, Csiba L, Vicaut E, Woo KS, Zannad F, Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th ESC (2004) Mannheim intima-media thickness consensus. Cerebrovasc Dis 18(4):346–349. doi: 10.1159/000081812 CrossRefPubMedGoogle Scholar
- 22.Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Fatar M, Hernandez RH, Jaff M, Kownator S, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS, Zannad F, Zureik M (2007) Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the advisory board of the 3rd and 4th watching the risk symposium, 13th and 15th European stroke conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 23 (1):75–80. doi: 10.1159/000097034
- 24.Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2(5):358–367CrossRefPubMedGoogle Scholar
- 25.Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T (2007) Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27(1):161–167. doi: 10.1161/01.ATV.0000252126.48375.d5 CrossRefPubMedGoogle Scholar
- 26.Altay S, Cakmak HA, Kemaloglu Oz T, Ozpamuk Karadeniz F, Turer A, Erer HB, Kilic GF, Keles I, Can G, Eren M (2016) Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study. Anatol J Cardiol. doi: 10.14744/AnatolJCardiol.2016.7307 Google Scholar
- 27.Tazaki R, Tanigawa J, Fujisaka T, Shibata K, Takeda Y, Ishihara T, Hoshiga M, Hanafusa T, Ishizaka N (2016) Plasma pentraxin 3 level is associated with plaque vulnerability assessed by optical coherence tomography in patients with coronary artery disease. Int Heart J 57(1):18–24. doi: 10.1536/ihj.15-248 CrossRefPubMedGoogle Scholar
- 29.Witasp A, Ryden M, Carrero JJ, Qureshi AR, Nordfors L, Naslund E, Hammarqvist F, Arefin S, Kublickiene K, Stenvinkel P (2013) Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS ONE 8(5):e63493. doi: 10.1371/journal.pone.0063493 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G, Donati MB, Lorenzet R (2002) Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol 22(5):782–787CrossRefPubMedGoogle Scholar
- 32.Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Cakar M, Egido J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ (2011) Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 6(4):785–792. doi: 10.2215/CJN.09231010 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Cakir E, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J (2008) ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 19(2):388–395. doi: 10.1681/ASN.2007040461 CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Kanbay M, Ikizek M, Solak Y, Selcoki Y, Uysal S, Armutcu F, Eryonucu B, Covic A, Johnson RJ (2011) Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol 33(4):325–331. doi: 10.1159/000324916 CrossRefPubMedPubMedCentralGoogle Scholar